Parker Institute for Cancer Immunotherapy(PICI) shared a post on LinkedIn:
“New PICI-supported research from the RADIOHEAD cohort and PICI Research Director EnJun Yang suggests that the medications patients take when starting immune checkpoint inhibitor (ICI) treatment may impact survival outcomes in real-world cancer care.
In a study of over 1,000 patients treated with ICIs, researchers found that polypharmacy – taking five or more medication classes at treatment initiation – was associated with worse overall survival. Baseline use of opioids and beta-blockers was also associated with reduced survival benefit, even after accounting for clinical factors.
These findings highlight how commonly prescribed medications may influence immunotherapy effectiveness and point to a potentially modifiable factor that could help improve cancer treatment outcomes beyond clinical trial settings.”
Title: Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort
Authors: Samantha Stone, Muhammad Zaki Fadlullah, Yuxin Zhao, Enjun Yang, Jordan McPherson, Roberta Florido, Grace Watkins, Aik Choon Tan, John E. Connolly, Ben J. Brintz, Samantha I. Liang, Zoe Quandt, Arabella Young
Read the Full Article.
Other articles from Parker Institute for Cancer Immunotherapy on OncoDaily.